ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Rating of "Buy" from Brokerages

ProQR Therapeutics N.V. (NASDAQ:PRQR - Get Free Report) has been given an average recommendation of "Buy" by the eight brokerages that are currently covering the firm, MarketBeat reports. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $8.00.

PRQR has been the topic of several research analyst reports. Evercore ISI initiated coverage on shares of ProQR Therapeutics in a research note on Tuesday, April 29th. They set an "outperform" rating and a $5.00 target price on the stock. Cantor Fitzgerald reissued an "overweight" rating and set a $8.00 target price on shares of ProQR Therapeutics in a research note on Friday. HC Wainwright raised their price objective on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a research note on Friday, March 14th. Chardan Capital reaffirmed a "buy" rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a research note on Friday, March 14th. Finally, Citigroup raised shares of ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price objective on the stock in a research note on Monday, March 10th.

Hedge Funds Weigh In On ProQR Therapeutics

Several large investors have recently modified their holdings of the business. M&T Bank Corp purchased a new position in ProQR Therapeutics in the 4th quarter worth approximately $330,000. Raymond James Financial Inc. purchased a new position in ProQR Therapeutics in the 4th quarter worth approximately $260,000. PNC Financial Services Group Inc. purchased a new position in ProQR Therapeutics in the 4th quarter worth approximately $77,000. Platinum Investment Management Ltd. purchased a new position in ProQR Therapeutics in the 4th quarter worth approximately $4,076,000. Finally, Virtu Financial LLC purchased a new position in ProQR Therapeutics in the 4th quarter worth approximately $83,000. Hedge funds and other institutional investors own 32.65% of the company's stock.

ProQR Therapeutics Stock Down 5.6%

PRQR opened at $2.04 on Monday. ProQR Therapeutics has a twelve month low of $1.07 and a twelve month high of $4.62. The company has a fifty day moving average of $1.74 and a 200-day moving average of $1.96. The stock has a market cap of $214.63 million, a PE ratio of -5.83 and a beta of 0.31.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The company had revenue of $4.89 million for the quarter, compared to the consensus estimate of $4.90 million. ProQR Therapeutics had a negative return on equity of 53.49% and a negative net margin of 157.04%. Sell-side analysts anticipate that ProQR Therapeutics will post -0.31 EPS for the current fiscal year.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.